Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia

Pathology

Volumn 44, Issue 7, 2012, Pages 632-637

  Ghassemifar, Reza ^a,c   Forster, Luke ^a,c   Finlayson, Jill ^a,c   Calogero, Tony ^a,b   Augustson, Brad ^a,b   Joske, David ^a,b,c   Cull, Gavin ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bax ; Bax ; Bcl 2 ; Bcl 2 ; CLL; QReTi PCR

Indexed keywords

BAX PROTEIN, HUMAN; CD19 ANTIGEN; ISOPROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; ANTIGENS, CD19; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84872969753     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835a0142     Document Type: Article

References (24)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-7.
2. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95: 513-7.
3. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76: 935-8.
4. Pepper C, Hoy T, Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998; 28: 355- 61.
5. Aviram A, Rabizadeh E, Zimra Y, et al. Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000; 64: 80-4.
6. Molica S, Dattilo A, Giulino C, et al. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica 1998; 83: 1122-4.
7. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-3.
8. Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and highlevel expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820-8.
9. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9.
10. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004; 61: 2189-99.
11. Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010; 34: 837-42.
12. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-33.
13. Lithgow T, van Driel R, Bertram JF, Strasser A. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ 1994; 5: 411-7.
14. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-8.
15. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-72.
16. Hsu YT, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 1998; 273: 10777-83.
17. Fu NY, Sukumaran SK, Kerk SY, Yu VC. Baxbeta: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism. Mol Cell 2009; 33: 15-29.
18. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
19. Cartron PF, Oliver L, Martin S, et al. The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients. Hum Mol Genet 2002; 11: 675-87.
20. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001; 29: e45.
21. Korsmeyer SJ, Shutter JR, Veis DJ, et al. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993; 4: 327-32.
22. Reed JC, Cuddy M, Slabiak T, et al. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988; 336: 259-61.
23. Tanaka S, Saito K, Reed JC. Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J Biol Chem 1993; 268: 10920-6.
24. Borner C, Martinou I, Mattmann C, et al. The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J Cell Biol 1994; 126: 1059-68.